NEUCHATEL, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (NASDAQ: CELG) announced that its oral cancer drug REVLIMID (lenalidomide) has received recommendation for approval from the Australian Drug Evaluation Committee (ADEC) for use in combination with dexamethasone as a treatment for patients with multiple myeloma whose disease has progressed after one therapy. Multiple myeloma is the second most commonly diagnosed blood cancer.
